Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 162

1.

Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario.

Guan Q, Khuu W, Martins D, Tadrous M, Chiu M, Do MT, Gomes T.

Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):256-262. doi: 10.24095/hpcdp.38.6.07. English, French.

2.

Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.

Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM.

PLoS Med. 2018 Jun 11;15(6):e1002584. doi: 10.1371/journal.pmed.1002584. eCollection 2018 Jun.

3.

Association between perioperative beta blocker use and cancer survival following surgical resection.

Musselman RP, Bennett S, Li W, Mamdani M, Gomes T, van Walraven C, Boushey R, Al-Obeed O, Al-Omran M, Auer RC.

Eur J Surg Oncol. 2018 May 17. pii: S0748-7983(18)31066-7. doi: 10.1016/j.ejso.2018.05.012. [Epub ahead of print]

PMID:
29858097
4.

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.

Antoniou T, Macdonald EM, Yao Z, Gomes T, Tadrous M, Ho JM, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network.

BMC Musculoskelet Disord. 2018 May 22;19(1):160. doi: 10.1186/s12891-018-2076-9.

5.

Clinical indications associated with opioid initiation for pain management in Ontario, Canada: A population-based cohort study.

Pasricha SV, Tadrous M, Khuu W, Juurlink DN, Mamdani MM, Paterson JM, Gomes T.

Pain. 2018 Jun 4. doi: 10.1097/j.pain.0000000000001242. [Epub ahead of print]

PMID:
29762260
6.

Measuring the Burden of Opioid-related Mortality in Ontario, Canada.

Gomes T, Greaves S, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN.

J Addict Med. 2018 Apr 25. doi: 10.1097/ADM.0000000000000412. [Epub ahead of print] No abstract available.

PMID:
29697503
7.

Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study.

Tadrous M, Brahmania M, Martins D, Knowles S, Janssen HLA, Mamdani MM, Juurlink DN, Gomes T.

J Manag Care Spec Pharm. 2018 May;24(5):464-468. doi: 10.18553/jmcp.2018.24.5.464.

8.

Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.

Minhas R, Tadrous M, Elterman D, Gomes T.

Neurourol Urodyn. 2018 Apr 23. doi: 10.1002/nau.23469. [Epub ahead of print]

PMID:
29682790
9.

Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.

Tadrous M, Greaves S, Martins D, Mamdani MM, Juurlink DN, Gomes T.

CMAJ Open. 2018 Mar 14;6(1):E132-E138. doi: 10.9778/cmajo.20170132.

10.

Opioid prescribing and adverse events in opioid-naive patients treated by emergency physicians versus family physicians: a population-based cohort study.

Borgundvaag B, McLeod S, Khuu W, Varner C, Tadrous M, Gomes T.

CMAJ Open. 2018 Mar 1;6(1):E110-E117. doi: 10.9778/cmajo.20170151.

11.

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

Gomes T, Jain S, Paterson JM, Sketris I, Caetano P, Henry D; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.

Pharmacoepidemiol Drug Saf. 2018 May;27(5):520-525. doi: 10.1002/pds.4390. Epub 2018 Jan 23.

12.

Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study.

Tadrous M, Elterman D, Khuu W, Mamdani MM, Juurlink DN, Gomes T.

Can Urol Assoc J. 2018 Mar;12(3):E142-E145. doi: 10.5489/cuaj.4541. Epub 2017 Dec 22.

13.

Senior high-cost healthcare users' resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada.

Muratov S, Lee J, Holbrook A, Paterson JM, Guertin JR, Mbuagbaw L, Gomes T, Khuu W, Pequeno P, Costa AP, Tarride JE.

BMJ Open. 2017 Dec 26;7(12):e018488. doi: 10.1136/bmjopen-2017-018488.

14.

Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants.

Gao L, Tadrous M, Knowles S, Mamdani M, Paterson JM, Juurlink D, Gomes T.

Healthc Policy. 2017 Nov;13(2):68-78.

PMID:
29274228
15.

Impact of a Graduated Approach on Opioid Initiation and Loss of Earnings Following Workplace Injury: A Time Series Analysis.

Gomes T, Duesburry J, Theriault ME, Bain D, Singh S, Martins D, Juurlink DN.

J Occup Environ Med. 2017 Dec;59(12):1197-1201. doi: 10.1097/JOM.0000000000001187.

16.

Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis.

Gomes T, Mastorakos A, Paterson JM, Sketris I, Caetano P, Greaves S, Henry D; Canadian Network for Observational Drug Effect Studies Investigators.

CMAJ Open. 2017 Nov 22;5(4):E800-E807. doi: 10.9778/cmajo.20170104.

17.

Availability of naloxone in Canadian pharmacies:a population-based survey.

Cressman AM, Mazereeuw G, Guan Q, Jia W, Gomes T, Juurlink DN.

CMAJ Open. 2017 Nov 8;5(4):E779-E784. doi: 10.9778/cmajo.20170123.

18.

Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.

Amiche MA, Lévesque LE, Gomes T, Adachi JD, Cadarette SM.

J Bone Miner Res. 2018 Mar;33(3):419-429. doi: 10.1002/jbmr.3318. Epub 2017 Dec 11.

PMID:
29068496
19.

Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.

Tadrous M, Khuu W, Lebovic G, Stanbrook MB, Martins D, Paterson JM, Mamdani MM, Juurlink DN, Gomes T.

Ann Allergy Asthma Immunol. 2018 Jan;120(1):59-65.e2. doi: 10.1016/j.anai.2017.08.016. Epub 2017 Oct 3.

PMID:
28986124
20.

Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.

Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W.

PLoS Med. 2017 Oct 3;14(10):e1002396. doi: 10.1371/journal.pmed.1002396. eCollection 2017 Oct.

Supplemental Content

Loading ...
Support Center